Methimazole
Methimazole is a thioamide immunomodulatory anti-thyroid compound that is clinically used to treat hyperthyroidism and Graves’ disease. Methimazole is an irreversible inhibitor of thyroid peroxidase; it decreases levels of CXCL10 and downregulates expression of IFNγ receptors.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18944189
| Cas No. |
60-56-0 |
|---|---|
| Purity |
≥98% |
| Formula |
C4H6N2S |
| Formula Wt. |
114.17 |
| Chemical Name |
1,3-Dihydro-1-methyl-2H-imidazole-2-thione |
| IUPAC Name |
3-methyl-1H-imidazole-2-thione |
| Synonym |
Basolan; Favistan; Frentirox; Mercazole; Tapazole; Thycapsol; Strumazol |
| Melting Point |
146-148°C |
| Solubility |
Soluble in water (200 mg/mL), ethanol (200 mg/mL), or chloroform. Slightly soluble in ether or benzene. |
| Appearance |
White Crystal Powder |
Rivkees SA. Pediatric Graves disease: management in the post-propylthiouracil Era. Int J Pediatr Endocrinol. 2014;2014(1):10. PMID: 25089127.
Manna D, Roy G, Mugesh G. Antithyroid drugs and their analogues: synthesis, structure, and mechanism of action. Acc Chem Res. 2013 Nov 19;46(11):2706-15. PMID: 23883148.
Crescioli C, Cosmi L, Borgogni E, et al. Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. J Endocrinol. 2007 Oct;195(1):145-55. PMID: 17911406.
